AU2001273289B2 - Core formulation comprising pioglitazone hydrochloride and a biguanide - Google Patents

Core formulation comprising pioglitazone hydrochloride and a biguanide Download PDF

Info

Publication number
AU2001273289B2
AU2001273289B2 AU2001273289A AU2001273289A AU2001273289B2 AU 2001273289 B2 AU2001273289 B2 AU 2001273289B2 AU 2001273289 A AU2001273289 A AU 2001273289A AU 2001273289 A AU2001273289 A AU 2001273289A AU 2001273289 B2 AU2001273289 B2 AU 2001273289B2
Authority
AU
Australia
Prior art keywords
formulation
patient
core
metformin
pioglitazone hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001273289A
Other versions
AU2001273289A1 (en
Inventor
Akwete L. Adjei
Anthony J. Cutie
Yaping Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kos Life Sciences Inc
Original Assignee
Aeropharm Technology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeropharm Technology LLC filed Critical Aeropharm Technology LLC
Priority to PCT/US2001/021615 priority Critical patent/WO2003005995A1/en
Publication of AU2001273289A1 publication Critical patent/AU2001273289A1/en
Application granted granted Critical
Publication of AU2001273289B2 publication Critical patent/AU2001273289B2/en
Assigned to KOS LIFE SCIENCES, INC. reassignment KOS LIFE SCIENCES, INC. Request for Assignment Assignors: AEROPHARM TECHNOLOGY, INC.
Application status is Ceased legal-status Critical
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/501Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Description

WO 03/005995 PCT/US01/21615 Core Formulation Comprising Pioglitazone Hydrochloride and a Biguanide This application claims priority from U.S. provisional application Serial No. 60/201,057, filed May 1, 2000, which is incorporated herein by reference.

BACKGROUND OF THE INVENTION Field of the Invention This invention relates to a core formulation, and, more particularly, to a core formulation comprising a first layer comprising pioglitazone, which covers at least a portion of a core comprising a biguanide, metformin glucophage), with a modulating release polymer comprising a silicate.

Description of the Related Art Metformin and pioglitazone, or their salts such as the hydrochlorides, maleates, tartrates, etc., are two active ingredients of anti-diabetic drugs that are used to treat diabetic patients, e.g. human beings. These two active agents are administered orally to patients in need thereof in protocols calling for the single administration of either ingredient. Heretofore, there has not been revealed or hinted at combining both ingredients and certainly not a physically combined core formulation comprising both ingredients. The use of such a core formulation is advantageous to patients and prescribers because both medicaments are synergistic to each other in the body when used in the management of blood glucose control, diabetes. Furthermore, the use of a modulating agent, like silica gel, in the preparation, controls the rate of drug release over a clinically meaningful period to enable better control of the effect of the medicinal agents in such preparation.

SUMMARY OF THE INVENTION This invention relates to a core formulation, and, more particularly, to a core formulation comprising a first layer comprising pioglitazone hydrochloride, which covers at least a portion of a core comprising a biguanide, e.g. metformin, one or both of which are intimately dispersed in a silicate based modulating agent.

DETAILED DESCRIPTION OF THE INVENTION A typical biguanide is metformin. It typically is used clinically as a pharmaceutically acceptable salt, preferably the hydrochloride salt. A commercial form of metformin hydrochloride is available as glucophage. Its chemical name is N,N-dimethylimidodicarbonimidic diamide hydrochloride. Metformin WO 03/005995 PCT/US01/21615 2 hydrochloride is a hydrochloride salt of metformin base, and as used herein, "metformin" means the base compound as well as its pharmaceutically acceptable salts. Metformin is used clinically to manage non-insulin dependent diabetes mellitus or "NIDDM", particularly in patients who are not effectively treated with a sulfonylurea. While it is not chemically related to the sulfonylureas, it is routinely utilized in combination with a sulfonylurea, and has been shown to be synergistic in some cases. Other biguanides such as phenformin, buformin etc. can also be used.

Additionally, in the treatment of a diabetic patient the metformin, for example, and the pioglitazone hydrochloride are present in effective amounts to provide such treatment.

Metformin is an active ingredient for a commercially available drug employed to treat diabetes mellitus in a host or mammal, e.g. a human being, another animal. The typical daily effective dose for the oral treatment of a mammal, a human, ranges from about 500 mg to about 2550 mg. Typically, the dose is a single dose of about 500 mg to about 850 mg.

Pioglitazone hydrochloride, (ACTOS®), is an active ingredient for a commercially available drug employed to treat diabetes mellitus in a host, e.g. a human being. The typical daily effective dose for the oral administration to a mammal, e.g. a human being, ranges from aboutl5 mg to about 45 mg, given as a single dose.

Silicates are pharmaceutical excipients generally regarded as safe and used therefore to prepare a variety of pharmaceutical systems well documented in the patent literature. In this regard, reference is made to Remington's Pharmaceutical Sciences, 18 t1 Edition, Inorganic Pharmaceutical Chemistry, Silicon, pp 340-341, 1990.

Heretofore, the silicates have not been shown to modulate the release of the hypoglycemic drugs metformin and pioglitazone hydrochloride when administered together to try to improve the control and effectiveness of either drug, although co-administration of the two has been proposed [Whitcomb; et al., United States Patent No. 6,011,049]. However, a combined form of the drugs, i.e. a single integral unit thereof has not heretofore been reported. The present invention provides such a single integral unit in the form of a core formulation.

WO 03/005995 PCT/US01/21615 3 A typical silicate for this purpose is Purified Siliceous Earth (National Formulary XVI), also known in some forms as silica gel or fumed silica.

It is typically used in oral pharmaceutical preparations as a bulking agent. As used herein, "silicate" means silicic acid, disilicic acid, tricisilic acid, metasilicic acid, and orthosilicic acid in their free or salt forms; silicon dioxide in either of its amporphous, crystalline, or precipitated forms; diatomacous earth; Fuller's earth, Kieselhurh, Celite; talc; attapulgite; micas; clays such as montmorilonite (Montmorilonite

T

kaolin, aluminum oxide (Hydrargilite), bentone (BentoniteTM), bentonite (Bentonite Magma

T

and pumice; silanes and siloxanes. These are used typically as adsorbents, carriers, dispersants, fillers, thickeners.

As indicated above, the relative concentrations of each drug is such that a first layer comprising pioglitazone hydrochloride is prepared. The first layer covers at least a portion of a core comprising metformin with a portion or all of the amount of the silicate. Depending upon the rate of administration of the core preparation, the metabolism of the patient destined to be treated, and the desired concentrations of each ingredient for each drug, the first layer may cover only a portion of the core or encompass the entire core. For example, one quarter of the core to about three fourths of the tablet core. The first layer should comprise pioglitazone hydrochloride with or without any silicate, because its dose requirement is lower compared to metformin. Additionally, pioglitazone hydrochloride is slightly non-polar, its solubility rate is slower, and its absorption rate thus is dependent on its dissolution rate in the contents of the gastrointestinal tract compared with metformin.

It is to be understood, depending upon the desired rate of administration to the patient, either the first layer or the core may additionally contain a mixture of the two active ingredients or both the first layer and the core may contain the two active ingredients with different and varying concentrations of one or both active ingredients.

The first layer of the core comprises pioglitazone hydrochloride in an amount of about 0.01 to about 20% of the total weight of the core formulation, whereas, the metformin in the core is present in an amount of about 10% to about 97.5% of the total weight of the core formulation.

WO 03/005995 WO 03/05995PCT/US01/21615 4 Where combinations of the two active ingrdients are present in the first layer and/or the core, the amnounts of pioglitazone hydrochloride range from about 1 mg to about 45 mg whereas the metformin ranges from about 100 mg to about 2550 mg.

Finally, it is to be understood that a third pharmacologically active material, e.g. a drug, such as for example a sulfonylurea,an c-glucosidase inhibitor, a meglitinide, and an ACE inhibitor may be employed in an admixture with the active ingredients in the first layer and/or the core.

The aipha.-glucosidase inhibitors [Jean-Bernard Ducep et al., US Patent No. 5,504,078], bisgiucosylmoranoline derivatives [TJK Patent No. GB 2 088 365 and glucosylmoranoline derivatives [European Patent No. 87112480.6] include the following medlicaments: 1 .5-Dideoxy-4-O(.alpha.,D-glucopyranosyl)- 1 ,5-[6,7-dideoxy-7-D-glucoheptopyranosyl)imino]-D-gl,,ucitol; 1 .5-Dideoxy-4- O(.alpha. ,D-glucopyranosyl)- 1,5-[(1-deoxy-D-fructofuranosyl)imino]-D-glucitol; 1 .5-Dideoxy-4-O(.alpha. ,D-glucopyranosyl)- 1,5-[(4-deoxy-4-Dglucopyranosyl)im-ino]-D-glucitol; 1 .5-Dideoxy-4-O(.alpha. ,D-glucopyranosyl)-N- 16-deoxy-1 -(6-O-D-glucopyranosyl)-.alpha.-D-glucopyranosyl]- 1, glucitol; 1 .5-Dideoxy-4-O(.alpha.,D-glucopyranosyl)-N-[6,7-clideoxy-l-(6-O-Dglucopyranosyl)-7-.alpha.-D -glucoheptopyranosyl]- 1,5-imiino-D-glucitol; Dideoxy-4-O(. alpha. ,D-glucopyranosyl)-l ,5-[(4-deoxy-4-Dglucopyranosyl)methylimino] -D-glucitol; 1 .5-Dideoxy-4--O(.alpha.,Dglucopyranosyl)-N-[4-deoxy-l-(4-O-D-glucopyranosyl)-.alpha.-D-glucopyranosyl]- 1 ,5-imino-D-glucitol; 1 .5-Dideoxy-4-O(.alpha. ,D-glucopyranosyl)- [2(l-Darabinofuranose)ethyljimino }-D-glucitol; 1 .5-Dideoxy-4-O(.alpha.,Dglucopyranosyl)-N-[4-deoxy-1-(6-O-D-glucopyranosyl)-.alpha.-D-glucopyranosyll 1 ,5-imino-D-glucitol; 1 .5-Dideoxy-4-O(.alpha.,D-glucopyranosyl)-N- {[4-deoxy- 1- (4-O-D-glucopyranosyl)-4-.alpha.-D -glucopyranosyllmethylj -1 1 .5-Dideoxy-4-O(.alpha. ,D-glucopyranosyl)-N-{ [4-deoxy-l1-(6-O-Dglucopyranosyl)-4-.alpha.-D -glucopyranosyllmethyl ,5-iniino-D-glucitol; Dideoxy-4-O(.alpha. ,D-glucopyranosyl)-l ,5-[(6-deoxy- 1 methyl-6-B-Dglucopyranosyl)-iniino-D -glucitol; 1 .5-Dideoxy-4-O(.alpha. ,D-glucopyranosyl)- [(6,7-dideoxy-1-O-methyl-7-B3-D-glucoheptopyranosyl) imrino]-D-glucitol; WO 03/005995 WO 03/005995PC T/USO1/2 16 Dideoxy-4-O(.alpha. ,D-glucopyranosyl)- 1,5-[(1-deoxy-2-0-methyl-B-Dfructofuranosyl)imino]-D-glucitol, 1 .5-Dideoxy-4-O(.alpha.,D-glucopyranosyl)-1 [(4-deoxy- 1-0-methyl-4-13-D-glucopyranosyl)imino] -D-glucitol; I .5-Dideoxy-4alpha. ,D-glucopyranosyl)-N-[6-deoxy- 1-(1 -O-methyl-6-O-13-D-glucopyranosyl)- .alpha.-D -glucopyranosyl]-1 ,5-imino-D-glucitol; 1 .5-Dideoxy-4-0(.alpha. ,Dglucopyranosyl)-N -[6,7-dideoxy- 1 -O-methyl-6-O-B-D-glucopyranosyl)-7-. alpha. D-glucoheptopyranosyll-1 ,5-imino-D-glucitol; 1 .5-Dideoxy-4-0(.alpha. ,Dglucopyranosyl)-1 ,5-II(4-deoxy- 1-0-methyl-4-B-D-glucopyranosyl)methylimino]-Dglucitol; 1 .5-Dideoxy-4-0(.alpha. ,D-glucopyranosyl)-N-[4-deoxy-l-(1 -0-methyl-4- 0-8-D-glucopyranosyl)-. alpha. -D -glIucopyranosyl]-1,5-iniino-D-glucitol; Dideoxy-4-O(.alpha. ,D-glucopyranosyl)- 1,5- 1-0-methyl- 1-1-Darabinofuranosyl)ethyl]imino} -D-glucitol; 1 .5-Dideoxy-4-O(.alpha.,Dglucopyranosyl)-N-[4-deoxy-1 -0-methyl-6-0-3-D-glucopyranosyl)-.alpha.-Dglucopyranosyl]-1 ,5-imiino-D-glucitol; 1 .5-Dideoxy-4-O(.alpha.,D-giucopyranosyl)- N- [4-deoxy- 1-(t-0-iethyl-4-0-3-D-glucopyranosyl)-4- .alpha.-Dglucopyranosylimethyl ,5-imiino-D-glucitol; 1 .5-Dideoxy-4-0(.alpha. ,Dglueopyranosyl)-N- [4-deoxy- 1-O-methyl-6-0-B-D-glucopyranosyl)-4-.alpha.-Dglucopyranosyl]methyl 1-1 ,5-imino-D-glucitol; 1 .5-Dideoxy-6-O(.alpha. ,Dglucopyranosyl)-1 ,5-[6,7-dideoxy-7-D-glucoheptopyranosyl)imino]-D-glucitol; Dideoxy-6-O(.alphla. ,D-glucopyranosyl)- 1,5- -deoxy-D-fructofuranosyl)iniino]-Dglucitol; 1 .5-Dideoxy-6-0(.alpha.,D-glucopyranosyl)-l ,5-[(4-deoxy-4-Dglucopyranosyl)imino]-D-glucitol; 1 .5-Dideoxy-6-O(.alpha.,D-glucopyranosyl)-N- [6-deoxy- 1 -(6-O-D-glucopyranosyl)-. alpha. -D-glucopyranosyl] 1 glucitol; 1 .5-Dideoxy-6-0(.alpha. ,D-glIucopyranosyl)-N-[6,7-dideoxy-1-(6-0-Dglucopyranosyl)-7-.alpha.-D -glucoheptopyranosyll-1 ,5-imnino-D-glucitol; Dideoxy-6-O(.alpha. ,D-glucopyranosyl)- 1,5- [(4-deoxy-4-Dglucopyranosyl)methylimino]-D-glucitol; I .5-Dideoxy-6-0(.alpha. ,Dglucopyranosyl)-N-14-deoxy--(4-0-D-glucopyranosyl)-.alpha.-D-glucopyranosyl]- 1 .5-Dicleoxy-6-0(. alpha.,D-glucopyranosyl)- 1,5- -Darabinofuranose)ethyl]imino }-D-glucitol; 1 .5-Dideoxy-6-O(.alpha. ,Dglucopyranosyl)-N-[4-deoxy-1-(6-0-D-glucopyranosyl)-.alpha.-D-glucopyranosyl]- 1 .5-Dideoxy-6-0(.alpha.,D-glucopyranosyl)-N- {[4-deoxy-1 WO 03/005995 WO 03/05995PCT/USOI/21615 6 (4-O-D-glucopyranosyl)-4-.alpha.-D -glucopyranosylilmethyl I1-1 1 .5-Dideoxy-6-O(.alpha. ,D-glucopyranosyl)-N- [4-deoxy-1 glucopyranosyl)-4-.alpha.-D -glucopyranosyljmethyl 1-1 ,5-imino-D-glucitol; Dideoxy-6-O(.alpha.,D-glucopyranosyl)- 1,5-II(6-deoxy- 1-O-methyl-6-B-Dglucopyranosyl) -imino-D-glucitol; 1 .5-Dideoxy-6-O(.alpha. ,D-glucopyranosyl)-1 [(6,7-dideoxy- 1-O-methyl-7-B3-D-glucoheptopyranosyl) imino]-D-glucitol; Dideoxy-6-O(.alpha.,D-glucopyranosyl)-1 -deoxy-2-O-methlyl-B-Dfructofuranosyl)imino]-D-glucitol; 1 .5-Dideoxy-6-O(.alpha.,D-glucopyranosyl)- [(4-deoxy-1-O-methyl-4-B--D-glucopyranosyl)im-ino]-D-glucitol; 1 .5-Dideoxy-6- O(.alpha. ,D-glucopyranosyl)-N-16-deoxy- 1-(1 -O-methyl-6-O-13-D-glucopyranosyl)- .alpha.-D -gluicopyranosyl] -1 ,5-im-ino-D-gluci tol; 1 .5-Dideoxy-6-O(.alpha. ,Dglucopyranosyl)-N-[6,7-dideoxy-1 -(1-O-miethyl-6-O-B-D-glucopyranosyl) -7- .alpha.-D-glucoheptopyranosyl]- 1,5-imino-D-glucitol; 1 .5-Dideoxy-6-O(.alpha. ,Dglucopyranosyl)-1 [(4-deoxy- 1 methyl-4-i3-D-glucopyranosyl)methylimino]-Dglucitol; 1 .5-Dideoxy-6-O(.alpha. ,D-glucopyranosyl)-N-[4-deoxy- 1-(1-O-methyl-4- O-1-D-glucopyranosyl)-. alpha. -D -glucopyranosylj-1 ,5-iniino-D-glucitol; Dideoxy-6-O(.alpha. ,D-glucopyranosyl)-1 1 methyl-1-B-Darabinofuranosyl)ethyllimino }-D-glucitol; 1 .5-Dideoxy-6-O(.alpha.,Dglucopyranosyl)-.N-[4-deoxy-1 -O-methyl-6-O-B-D-glucopyranosyl)-.alpha.-D glucopyranosyl]-1 ,5-im-ino-D-glucitol; 1 .5-Dideoxy-6-O(.alpha. ,D-glucopyranosyl)- N-([4-deoxy- 1-(l -O-methyl-4-O-1-D-glucopyranosyl)-4-. alpha. -Dglucopyranosyllmethyl ,5-imnino-D-glucitol; I .5-Dideoxy-6-O(.alpha. ,Dglcprnsl--[-ex-1( 0mtyl60BDguoyaoy)4.apa D glucopyranosyllmethyl The list of medicaments includes acid addition salt forms with such inorganic acids, such as, for example, hydrochloric, hydrobromic, sulfuric, phosphoric and like acids; with organic carboxylic acids such as, for example, acetic, propionic, glycolic, lactic, pyruvic, malonic, succinic, fumaric, maleic, tartaric, citric, ascorbic, maleic, hydroxymaleic, dihydroxymaleic, benzoic, 2acetoxybenzoic, mandelic and like acids; and with organic sulfonic acids such as methanesulfonic acid and p-toluenesulfonic acid.

WO 03/005995 PCT/US01/21615 7 The sulfonylureas are a class of compounds that have been widely employed to treat diabetes. Such compounds are well known, for example as described in U.S. Pat. Nos. 3,454,635; 3,669,966; 2,968,158; 3,501,495; 3,708,486; 3,668,215; 3,654,357; and 3,097,242. Especially preferred sulfonylureas to be employed in the combinations or core formulations of this invention are glyburide, gliquidone, glipizide, tolbutamide, tolazamide, glisoxepid, chlorpropamide, glibornuride, gliclazide, glimepiride, phenbutamide, and tolcyclamide. Other medicaments, such as, for example, an antibiotic, a vitamin, a drug that works on the heart or in the liver, may be admixed with the active ingredients in the first layer and/or the core.

As indicated above, the modylating silicate polymer, e.g. silica gel, e.g. may be associated with the metformin core alone or with the first layer alone or with both the metformin and pioglitazone hydrochloride. The type of association as well as the concentration of the modulating agent is dependent upon the concentrations of the core active ingredient, and the layer active ingredient, the degree of coverage of the core by the first layer and the desired rate of administration of every active ingredient.

The resultant core having the first layer thereon is prepared by any conventional means known in the pharmaceutical art, e.g. compression, tabletting technology, spraying technology, or encapsulation in a pharmaceutically acceptable presentation, such as a gelatin capsule. In particular, typically, the core formulation of the present invention is preferably fabricated by compression into a tablet.

The resultant core formulation of the present invention is useful to treat diabetes mellitus. Surprisingly the resultant core formulation of the invention is as user friendly and clinically effective as compared to the administration of metformin alone or pioglitazone hydrochloride alone as demonstrated by coadministration of the two agents [Whitcomb; et al., United States Patent No.

6,011,049], where in general, the incidence of adverse events was not influenced by age or menopausal status; and further, patients treated with the combination therapy attained better glycemic control than with either monotherapy.

It is to be understood, however, that for any particular subject being treated, a mammal, specific dosage regimens should be adjusted according to WO 03/005995 PCT/US01/21615 8 the individual need. It is further to be understood that the dosages set forth herein are exemplary only and that they do not, to any extent limit the scope of the practice of the present invention.

The core formulation of the present invention may be administered orally, for example, with inert diluent or with an edible carrier. For the purpose of oral therapeutic administration, the core formulation may have other excipients incorporated therein. The subject core formulation may also contain the following adjuvants: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel®, corn starch and the like; a lubricant such as magnesium stearate or Sterotex; a glidant such as colloidal silicon dioxide; and a sweetening agent such as sucrose or saccharin may be added or a flavoring agent such as peppermint, methyl salicylate or orange flavoring.

The subject core formulation of the invention may contain other various materials which modify the physical form of the dosage unit (the subject core formulation), for example, as coatings. Thus, the subject core formulation of the present invention may be coated with sugar, shellac or other enteric coating agents. Materials used in preparing these various compositions should be pharmaceutically pure and non-toxic in the amounts used.

In an alternative embodiment of the present invention, the resultant core formulation (having a first layer completely or partially covering the core), is treated whereby an outer shell is formed, at least a portion of which comprises the biodegradable modulating silicate material is presemt in an amount having a predetermined rate of degradation or metabolism in the host being present treated.

The silicate material is a high molecular weight compound, which is physiologically acceptable and excreted from the body of the human being or other animal almost intact.

The biodegradable silicate material, comprising the outer shell, having a predetermined rate of degradation or metabolism or break down, is selected from silic acid and its derivatives, examples of which include those listed previously. Other materials well known in the art, which do not react with metformin and/or pioglitazone hydrochloride such as biodegradable polymers, like WO 03/005995 PCT/US01/21615 9 polyorthoesters, polyanhydrides, polyamides based on glutamic acid, polyalkyl cyanoacrylates, polyesters of lactic and glycolic acid, polyactide polymers, cellulosic polymers, polyvinyl acetate, polyvinyl alcohol, polyvinylchloride, natural and synthetic rubbers, polyacrylates, polystyrene, etc. may be used. Additionally, reference is made to U.S. Patents Nos. 4,166,800, and 4,389,330, which disclose additional shell forming materials and are incorporated hereinto by reference in their entirety.

The shell encapsulating the particles of pioglitazone hydrochloride of the first layer and/or the particles of metformin of the core is obtained by any conventional microencapsulation process whereby microspheres of metformin and/or pioglitazone hydrochloride are formed, e.g. a solvent removal process, a phase separation technique, coacervation etc. In this regard reference is made to U.S. Patents Nos. 4,166,800 and 4,389,330, Conte et al, J. Controlled Release, vol.

26, (1993), pages 39-47; and U.S. Patent No. 4,839,177; all of which are incorporated hereinto by reference in their entirety.

In a variation of the above alternative embodiment, the resultant core formulation is treated whereby only the top surface area of the first layer comprising pioglitazone hydrochloride has a shell coating thereon. In this regard, reference is made to U.S. Patent No. 5,916,584, incorporated hereinto by reference in its entirety, which describes the process for forming such a shell. The resulting core formulation having the first layer encapsulated by the shell comprising the shell material, is one which provides a delay time prior to release of the active ingredients, i.e.

pioglitazone hydrochloride and metformin, to the patient being treated for diabetes mellitus.

In a second alternative embodiment of the present invention, the resultant core formulation (having a first layer completely or partially covering the core) is treated whereby an outer shell comprising a natural polysaccaride, in its free acid a or salt form such as guar gum; gum arabic; gum karaya; gum Benjamin, plantago ovata gum; agar; carrageenan; cellulose; gelatin; pectin; or galacturonic acid is formed which encloses the particles of the first layer and/or the core.

Silicates are naturally occurring polymers consisting of silicon chains. These polymers have the propensity to absorb water thus swelling to WO 03/005995 PCT/US01/21615 become gel-like structures in solution. The gel dissolves slowly thus releasing its drug payloads in a dissolution controlled manner.

The silicate shell, provides excellent stability to the core formulation while at the same time modulates drug release. Upon ingestion by a patient being treated, the silicate shell swells to become a gel-like structure in solution in the body of the patient, e.g. the stomach. The gel ultimately dissolves slowly, e.g. typically, in several minutes to a few hours, usually within a day, releasing its drug payload, e.g. metformin and/or pioglitazone hydrochloride in a dissolution controlled manner.

The shell is formed using any conventional coating technique, as previously discussed, see U.S. Patents Nos. 4,166,800 and 4,839,177.

The rate of release is dependent on the shell's thickness and amount of the polymeric material contained therein for a particular medicament formulation.

Typically, for a release of of about 2 to 6 hours, the thickness ranges from about 0.0001 mm to about 1 mm with a concentration of the polymeric material ranging from about 10 ppm to about 100,000 ppm.

In a variation of the above second alternative embodiment, the polysaccharide polymeric material, e.g. silicate, may be incorporated into or combined or mixed with the first layer comprising metformin and/or the core of pioglitazone in an effective amount to provide the desired stability and controlled release of these medicaments. Typically, the silicate is provided in an amount ranging from about 10 ppm to about 100,000 ppm,in one both or of the medicaments to effect a desired release profile e.g. 15 minutes to about 12 hours of one or both of the medicaments of the core.

As discussed above, it is to be understood that the resultant core formulation may be treated with the polymeric material whereby only the top surface area of the first layer comprising poglitazone hydrochloride has a coating hereon. In this regard reference is again made to U.S. Patent No. 5,916,584. Thus as described above a delay time is provided prior to release of the release of the medicaments.

It is to be understood that for either metformin or pioglitazone, any pharmaceutically acceptable form thereof can be employed. Such a form encompasses the free acids, free bases, salts and various hydrate forms, including WO 03/005995 PCT/US01/21615 11 semi-hydrate forms of these medicaments, as well as other pharmaceutical materials which are used in the formulation process as acceptable excipient materials generally known to those skilled in the art.

It is understood that any one of the biguanides, i.e. drugs having the action of the stimulation of anaerobic glycolysis, is covered by this invention as these, like metformin, increase the sensitivity to insulin in peripheral tissues of the host, e.g. a human being or another animal. These compounds also are involved in the inhibition of glucose absorption from the intestine, suppression of hepatic gluconeogenesis, and inhibition of fatty acid oxidation. Examples of other typical biguanides included in this application are phenformin, buformin etc.

Claims (17)

1. A core formulation comprising, a first layer comprising pioglitazone hydrochloride or a pharmaceutically acceptable salt thereof as an active ingredient, a core, at least a portion of which is enclosed by said first layer, comprising a biguanide as an active ingredient; and a modulating polymer comprising a silicate which is associated with at least one of said active ingredients.
2. The formulation of claim 1 wherein said polymer is associated by forming an enclosing shell.
3. The formulation of claim 1 wherein said polymer is associated by being combined with said at least one of said active ingredients.
4. The formulation as defined in claim 1 wherein said polymer is associated by covering at least a portion of said first layer to provide a predetermined delay in the time period of release of at least said pioglitazone hydrochloride. The formulation as defined in claim 1, wherein said modulating polymer comprises a silicate selected from the group consisting of silicic acid, disilicic acid, trisilic acid, metasilicic acid, and orthosilicic acid in their free or salt forms; silicon dioxide in either of its amporphous, crystalline, or precipitated forms; diatomacous earth; Fuller's earth; Kieselhurh, Celite; talc; attapulgite; micas; montmorilonite, kaolin, aluminum oxide (Hydrargilite), bentonite, pumice; silanes and siloxanes and a mixture of any of the foregoing polymers.
6. The formulation as defined in claim 5, wherein said biguanide is metformin.
7. The formulation as defined in claim 6, wherein said pioglitazone hydrochloride is present in an amount ranging from about 1 mg to about 45 mg; said metformin is present in an amount ranging from about 10 to about 4000 mg.
8. The formulation as defined in claim 6, wherein said pioglitazone hydrochloride and/or said metformin are present as biodegradable microspheres. WO 03/005995 PCT/US01/21615 13
9. A method of administering pioglitazone hydrochloride and metformin to a mammal, which comprises treating the mammal with the formulation defined in claim 6. A method of producing a controlled release formulation, which comprises: producing a hollow outer shell comprising a modulating polymer material comprising a silicate having a predetermined rate of degradation to provide a predetermined delay in the time period of release of the contents destined to be enclosed by said shell; inserting a core comprising metformin and having an outer layer comprising pioglitazone hydrochloride partially enclosing said core, into said hollow outer shell; and sealing said core within said hollow outer shell.
11. A method of producing a controlled release formulation, which comprises: forming a core of the metformin; depositing a layer of pioglitazone hydrochloride on at least a portion of a surface of said core; combining a modulating polymer material with at least one of said metformin or said proglitazone hydrochloride.
12. A method of treating diabetes mellitus in a patient in need thereof, which comprises administering to the patient the formulation of claim 1 wherein said active ingredients are each present in an effective amount.
13. A pharmaceutical composition comprising an effective amount of pioglitazone hydrochloride medicament combined with an effective amount of metformin medicament where at least one of said medicaments is combined with an effective modulating amount of a modulating polymer.
14. A method of treating diabetes mellitus in a patient in need thereof, which comprises, administering to the patient the composition of claim 13.
15. A pharmaceutical composition comprising an effective amount of pioglitazone hydrochloride medicament combined with an effective WO 03/005995 PCT/US01/21615 14 amount of phenformin medicament where at least one of said medicaments is combined with an effective modulating amount of a modulating polymer.
16. A pharmaceutical composition comprising an effective amount of pioglitazone hydrochloride medicament combined with an effective amount of buformin medicament where at least one of said medicaments is combined with an effective modulating amount of a modulating polymer.
17. A method of treating diabetes mellitus in a patient in need thereof, which comprises, administering to the patient the composition of claim 1.
18. A method of treating diabetes mellitus in a patient in need thereof, which comprises, administering to the patient the composition of claim 6.
19. A method of treating diabetes mellitus in a patient in need thereof, which comprises, administering to the patient the composition of claim 1 wherein the biguanide is phenformin. A method of treating diabetes mellitus in a patient in need thereof, which comprises, administering to the patient the composition of claim 1 wherein the biguanide is buformin.
AU2001273289A 2001-07-10 2001-07-10 Core formulation comprising pioglitazone hydrochloride and a biguanide Ceased AU2001273289B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2001/021615 WO2003005995A1 (en) 2001-07-10 2001-07-10 Core formulation comprising pioglitazone hydrochloride and a biguanide

Publications (2)

Publication Number Publication Date
AU2001273289A1 AU2001273289A1 (en) 2003-05-22
AU2001273289B2 true AU2001273289B2 (en) 2004-10-07

Family

ID=21742689

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001273289A Ceased AU2001273289B2 (en) 2001-07-10 2001-07-10 Core formulation comprising pioglitazone hydrochloride and a biguanide

Country Status (6)

Country Link
EP (1) EP1429747A4 (en)
JP (1) JP2004536843A (en)
AU (1) AU2001273289B2 (en)
CA (1) CA2453775A1 (en)
MX (1) MXPA04000180A (en)
WO (1) WO2003005995A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1429732A4 (en) * 2001-07-10 2005-01-26 Kos Life Sciences Inc A core formulation
EP1552832A1 (en) * 2002-07-11 2005-07-13 Takeda Pharmaceutical Company Limited Process for producing coated preparation
BRPI0407074A (en) 2003-01-29 2006-01-24 Takeda Pharmaceutical Method for producing a coated preparation, coated preparation and method for improving the dissolution of pioglitazone hydrochloride in a preparation coated with pioglitazone hydrochloride
GB0316940D0 (en) * 2003-07-19 2003-08-27 Ward Warren Treatment of skin and other medical conditions
JP2007516948A (en) * 2003-07-19 2007-06-28 ワード,ウォレン Use of it is liquid impermeable composition comprising a component coated with a gas permeable layer, the composition in the treatment of skin and other exocrine gland disease
US20070078170A1 (en) * 2003-08-28 2007-04-05 Khanduri Chandra H Process for the preparation of pioglitazone
EP1838273A4 (en) * 2005-01-10 2013-02-20 Elc Man Llc Discontinuous surface coating for particles
MXPA05014092A (en) * 2005-12-20 2007-06-20 Leopoldo De Jesus Espinosa Abdala Pharmaceutical compositions containing derivative substances of thiazolidinediones combined with a biguanide for use in type 2 diabetes mellitus.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166043A (en) * 1995-06-20 2000-12-26 Takeda Chemical Industries, Ltd. Pharmaceutical composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416774B1 (en) * 1996-05-09 2002-07-09 The Trustees Of The University Of Pennsyvania Hollow bone mineral-like calcium phosphate particles
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6358531B1 (en) * 1999-02-01 2002-03-19 The Curators Of The University Of Missouri Method for preparing porous shells or gels from glass particles
US6780432B1 (en) * 2000-05-01 2004-08-24 Aeropharm Technology, Inc. Core formulation
US6451342B2 (en) * 2000-05-01 2002-09-17 Aeropharm Technology Incorporated Core formulation comprised of troglitazone and a biguanide
EP1429732A4 (en) * 2001-07-10 2005-01-26 Kos Life Sciences Inc A core formulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166043A (en) * 1995-06-20 2000-12-26 Takeda Chemical Industries, Ltd. Pharmaceutical composition

Also Published As

Publication number Publication date
WO2003005995A1 (en) 2003-01-23
JP2004536843A (en) 2004-12-09
CA2453775A1 (en) 2003-01-23
EP1429747A4 (en) 2005-01-05
EP1429747A1 (en) 2004-06-23
MXPA04000180A (en) 2004-11-22

Similar Documents

Publication Publication Date Title
ES2222522T3 (en) Migraine treatment using metoclopramide and an NSAID.
KR101595169B1 (en) Formulation comprising metformin and vildagliptin
US6558701B2 (en) Multilayer tablet for administering a fixed combination of tramadol and diclofenac
CN1098104C (en) New oral pharmaceutical dosage form
US8414921B2 (en) Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
AU2007319471B2 (en) Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
JP4925074B2 (en) A pharmaceutical composition comprising a mirtazapine and one or more selective serotonin reuptake inhibitors
RU2226396C2 (en) Solid dosed medicinal formulation for oral using containing combination of metformin and glibenclamide
RU2179453C2 (en) Peroral pharmaceutical medicinal forms including proton pump inhibitor and antacid substance or alginate
AU2010242748B2 (en) Orally disintegrating tablet compositions comprising combinations of high and low-dose drugs
AU2004226955B2 (en) Novel composition and use
EP1594499B1 (en) Dosage forms containing a proton pump inhibitor, a nsaid, and a buffer
US20060134206A1 (en) Oral compositions for treatment of diseases
AU2004258984B2 (en) Immediate-release formulation of acid-labile pharmaceutical compositions
US20090253752A1 (en) Combination of dpp-iv inhibitor, ppar antidiabetic and metmorfin
KR100566701B1 (en) Use of alpha-glucosidase inhibitors for treating high-risk impaired glucose tolerance
EP2486918A2 (en) Pharmaceutical composition with both immediate and extended release characteristics
US6677358B1 (en) NIDDM regimen
US20030124061A1 (en) Pharmaceutical safety dosage forms
CN100469366C (en) Pharmaceutical formulation comprising a proton pump inhibitor and antacids
US6756057B2 (en) Amoxicillin and potassium clavulanate dosage form
EP0869796B1 (en) A glibenclamide-metformin combination for the treatment of diabetes mellitus of type ii
US20050232987A1 (en) Dosage form containing a morphine derivative and another drug
EP0514452B2 (en) Use of insulin sensitizing agents to treat hypertension
US5593685A (en) Ranitidine compositions

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: KOS LIFE SCIENCES, INC.

Free format text: FORMER APPLICANT(S): AEROPHARM TECHNOLOGY, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired